BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23170016)

  • 1. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Marousi S; Travasarou M; Karageorgiou CE; Gheuens S; Koralnik IJ
    Neurology; 2012 Nov; 79(21):2160; author reply 2160. PubMed ID: 23170016
    [No Abstract]   [Full Text] [Related]  

  • 2. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Gheuens S; Smith DR; Wang X; Alsop DC; Lenkinski RE; Koralnik IJ
    Neurology; 2012 May; 78(18):1390-3. PubMed ID: 22517104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
    Ercan MB; Kocer B; Altiparmak T; Arslan I
    Mult Scler; 2024 May; 30(6):760-762. PubMed ID: 38385206
    [No Abstract]   [Full Text] [Related]  

  • 5. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?
    Wattjes MP; Verhoeff L; Zentjens W; Killestein J; van Munster ET; Barkhof F; van Eijk JJ
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1176-7. PubMed ID: 23695498
    [No Abstract]   [Full Text] [Related]  

  • 6. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
    Metz I; Radue EW; Oterino A; Kümpfel T; Wiendl H; Schippling S; Kuhle J; Sahraian MA; Gray F; Jakl V; Häusler D; Brück W
    Acta Neuropathol; 2012 Feb; 123(2):235-45. PubMed ID: 22057786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
    J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.
    Toorop AA; van Lierop ZYG; Strijbis EEM; Teunissen CE; Petzold A; Wattjes MP; Barkhof F; de Jong BA; van Kempen ZLE; Killestein J
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33051344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal supportive treatment in natalizumab-related PML in a MS patient.
    Lalive PH; Bridel C; Ferfoglia RI; Kaiser L; Du Pasquier R; Barkhof F; Haller S
    J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):354-5. PubMed ID: 24957322
    [No Abstract]   [Full Text] [Related]  

  • 10. The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab.
    Baheerathan A; McNamara C; Kalam S; Rane N; Barwick TD; Grote H; Nicholas R
    Neurology; 2018 Sep; 91(12):572-573. PubMed ID: 30224501
    [No Abstract]   [Full Text] [Related]  

  • 11. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
    Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
    Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
    Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
    Tan IL; McArthur JC; Clifford DB; Major EO; Nath A
    Neurology; 2011 Sep; 77(11):1061-7. PubMed ID: 21832229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.
    Tan LA; Lopes DK
    J Clin Neurosci; 2015 Oct; 22(10):1669-71. PubMed ID: 26115897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
    Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive multifocal leukoencephalopathy and natalizumab.
    Hellwig K; Gold R
    J Neurol; 2011 Nov; 258(11):1920-8. PubMed ID: 21647730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E; Louapre C; Lubetzki C; Papeix C
    Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Too much of a good thing? IRIS with natalizumab-associated PML.
    Berger JR
    Neurology; 2011 Sep; 77(11):1033-4. PubMed ID: 21832217
    [No Abstract]   [Full Text] [Related]  

  • 19. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
    Ropper AH
    N Engl J Med; 2012 May; 366(20):1938-9. PubMed ID: 22591300
    [No Abstract]   [Full Text] [Related]  

  • 20. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
    Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.